Advice
following a full submission:
adalimumab (Humira) is accepted for use within NHS Scotland for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.
Adalimumab improves symptoms of arthritis and psoriasis and may slow the progression of joint damage in patients with active psoriatic arthritis
Download detailed advice66KB (PDF)
Medicine details
- Medicine name:
- adalimumab (Humira)
- SMC ID:
- 218/05
- Indication:
- active and progressive psoriatic arthritis.
- Pharmaceutical company
- Abbott Laboratories
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 12 December 2005